Novotech, the leading global full-service clinical Contract Research Organization (CRO), has released a comprehensive report analyzing the global clinical trial and drug development landscape for ...

Mersana shares Phase 1 data on Emi-Le for TNBC and details FDA's Fast Track status for XMT-1660 in advanced HER2-low breast ...

The addition of camrelizumab to platinum-containing intensive neoadjuvant chemotherapy improved pathologic complete response ...

The increase in breast cancer rates among younger patients is occurring as the incidence of other early-onset cancers — ...

The FDA has granted fast track designation to emiltatug ledadotin for advanced or metastatic breast cancer treatment, as ...

Anixa Biosciences CEO Amit Kumar discusses the biotech’s plans for advancing a breast cancer vaccine in 2025. The cancer ...

REVEAL GENOMICS, S.L., a Barcelona-based biotechnology start-up seeking to revolutionize precision oncology through biomarker ...

CAMBRIDGE, MA—Mersana Therapeutics, Inc. (NASDAQ:MRSN) recently reported that Ashish Mandelia, the company's Vice President ...

在这项最新研究中，研究团队发现了一种小分子——CT-1，它是隐丹参酮（CTS）的衍生物，能够有效抑制三阴性乳腺癌（TNBC）的生长，同时显著降低肿瘤组织中 N2 型肿瘤相关中性粒细胞（N2 型 TAN）的比例。

Brian DeSchuytner, the Senior Vice President, Chief Operating Officer, and Chief Financial Officer of Mersana Therapeutics, Inc. (NASDAQ:MRSN), recently reported a transaction involving the company's ...

Mersana Therapeutics (MRSN) stock hits a 52-week low in reaction to early clinical results for its cancer drug Emi-Le in ...

Avacta is stepping up development of its peptide-drug conjugate (PDC), kicking off expansion cohorts in multiple tumor types ...